LMAT
NEUTRAL
$114.62
Live
LeMaitre Vascular, Inc. · NASDAQ
Target $111.22
(-3.0%)
$78.01
52W Range
$115.33
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$2.61B
P/E
45.48
ROE
15.8%
Profit margin
23.1%
Debt/Equity
0.47
Dividend yield
0.87%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
LMAT exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and exceptional liquidity, but it is currently facing a severe valuation disconnect. While the company shows strong growth (41.4% earnings growth) and high gross margins, the current price of $114.62 significantly exceeds both the Graham Number ($31.3) and the growth-based Intrinsic Value ($74.34). This premium is further complicated by heavy insider selling, including a large divestment by the CEO, and a bearish technical trend despite the price being near 52-week highs.
Key Strengths
Exceptional gross margins of 70.45%
Strong earnings growth (YoY +41.40%)
Extremely high liquidity with a current ratio of 12.89
Consistent track record of earnings beats (3 of last 4 quarters)
Low leverage with a Debt/Equity ratio of 0.47
Key Risks
Significant overvaluation relative to intrinsic value ($114.62 vs $74.34)
High PEG ratio (3.31) suggesting growth is already priced in
Aggressive insider selling totaling $23.70M
Bearish technical trend (10/100) indicating potential price exhaustion
High Price/Sales ratio (10.46) compared to typical industry standards
AI Fair Value Estimate
Based on comprehensive analysis
$76.5
-33.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
58
Moderate
20
85
80
60
45
AI Verdict
Growth-driven but overpriced
Key drivers: Strong profitability, Extreme valuation premium, Insider divestment
Confidence
90%
Value
20/100
Ref P/E 45.48, PEG 3.31, Graham Number $31.3
Positives
- Forward P/E is slightly lower than trailing
Watchpoints
- Price is 3.6x the Graham Number
- PEG ratio > 3.0
- P/S ratio is very high
Future
85/100
Ref Growth rates: Rev +15.7%, Earnings +41.4%
Positives
- Strong YoY revenue and earnings growth
- Consistent earnings surprises
Watchpoints
- Recent Q/Q EPS growth dip (-9.3%)
Past
80/100
Ref Historical trends and earnings track record
Positives
- Strong 5-year price appreciation (+140.7%)
- Consistent earnings beat history
Watchpoints
No urgent risks highlighted.
Health
60/100
Ref Piotroski F-Score 4/9
Positives
- Very low debt/equity
- Massive current ratio
Watchpoints
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Dividend
45/100
Ref Yield 0.87%, Payout 31.75%
Positives
- Sustainable payout ratio (31.75%)
Watchpoints
- Very low yield (0.87%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$114.62
Analyst Target
$111.22
Upside/Downside
-3.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LMAT and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
Primary
|
+140.7% | +121.7% | +42.2% | +33.8% | +6.0% | +5.7% |
|
HCM
HUTCHMED (China) Limited
Peer
|
-48.0% | -1.7% | +21.6% | +1.1% | +4.6% | -1.2% |
|
LFST
LifeStance Health Group, Inc.
Peer
|
-70.8% | -18.8% | -5.5% | +26.7% | -3.6% | +1.4% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-59.8% | -70.9% | -22.3% | -23.8% | -15.1% | -5.6% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
LMA
LeMaitre Vascular, Inc.
Primary
5Y
+140.7%
3Y
+121.7%
1Y
+42.2%
6M
+33.8%
1M
+6.0%
1W
+5.7%
HCM
HUTCHMED (China) Limited
Peer
5Y
-48.0%
3Y
-1.7%
1Y
+21.6%
6M
+1.1%
1M
+4.6%
1W
-1.2%
LFS
LifeStance Health Group, Inc.
Peer
5Y
-70.8%
3Y
-18.8%
1Y
-5.5%
6M
+26.7%
1M
-3.6%
1W
+1.4%
APL
Apellis Pharmaceuticals, Inc.
Peer
5Y
-59.8%
3Y
-70.9%
1Y
-22.3%
6M
-23.8%
1M
-15.1%
1W
-5.6%
ARQ
Arcutis Biotherapeutics, Inc.
Peer
5Y
-30.1%
3Y
+98.3%
1Y
+53.6%
6M
+31.6%
1M
-14.4%
1W
-5.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
45.48
Forward P/E
35.99
PEG Ratio
3.31
P/B Ratio
6.63
P/S Ratio
10.46
EV/Revenue
9.77
EV/EBITDA
33.15
Market Cap
$2.61B
Profitability
Profit margins and return metrics
Profit Margin
23.13%
Operating Margin
21.77%
Gross Margin
70.45%
ROE
15.8%
ROA
6.76%
Growth
Revenue and earnings growth rates
Revenue Growth
+15.7%
Earnings Growth
+41.4%
Q/Q Revenue Growth
+15.68%
Q/Q Earnings Growth
+39.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.47
Low debt
Current Ratio
12.89
Strong
Quick Ratio
10.81
Excellent
Cash/Share
$15.77
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
71.7%
Op. Margin
29.2%
Net Margin
24.2%
Total Assets
$0.6B
Liabilities
$0.2B
Equity
$0.4B
Debt/Equity
0.56x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
92%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-25
$0.68
+2.4% surprise
2025-11-06
$0.75
+33.1% surprise
2025-08-05
$0.6
+6.1% surprise
Healthcare Sector Comparison
Comparing LMAT against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
45.48
This Stock
vs
87.11
Sector Avg
-47.8%
(Discount)
Return on Equity (ROE)
15.8%
This Stock
vs
-49.88%
Sector Avg
-131.7%
(Below Avg)
Profit Margin
23.13%
This Stock
vs
-9.43%
Sector Avg
-345.2%
(Weaker)
Debt to Equity
0.47
This Stock
vs
3.74
Sector Avg
-87.4%
(Less Debt)
Revenue Growth
15.7%
This Stock
vs
80.78%
Sector Avg
-80.6%
(Slower)
Current Ratio
12.89
This Stock
vs
3.72
Sector Avg
+246.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
NEUTRAL | $2.61B | 45.48 | 15.8% | 23.1% | $114.62 | |
|
HCM
HUTCHMED (China) Limited
|
NEUTRAL | $2.62B | 5.75 | 45.2% | 83.3% | $15.24 | Compare |
|
LFST
LifeStance Health Group, Inc.
|
NEUTRAL | $2.45B | 320.0 | 0.7% | 0.7% | $6.4 | Compare |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.42B | 105.22 | 7.5% | 2.2% | $18.94 | Compare |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | Compare |
LMAT
LeMaitre Vascular, Inc.
NEUTRAL
Mkt Cap
$2.6B
P/E
45.5
ROE
15.8%
Price
$114.62
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-11 | KAMKE TRENT G | Officer | Sale | 2,625 | $284,812 |
| 2026-03-11 | KAMKE TRENT G | Officer | Option Exercise | 2,625 | $93,135 |
| 2026-03-11 | ROBERTS DAVID BRIAN | President | Sale | 3,311 | $356,586 |
| 2026-03-10 | LEBLANC DORIAN PAUL CPA | Chief Financial Officer | Stock Award | 2 | - |
| 2026-03-02 | LEMAITRE GEORGE W | Chief Executive Officer | Gift | 5,000 | - |
| 2026-03-02 | LEMAITRE GEORGE W | Chief Executive Officer | Sale | 205,930 | $22,043,375 |
| 2026-02-27 | KAMKE TRENT G | Officer | Sale | 1,044 | $115,143 |
| 2026-02-27 | ROBERTS DAVID BRIAN | President | Sale | 8,464 | $903,958 |
| 2026-02-26 | ROUSH JOHN A | Director | Stock Award | 476 | - |
| 2026-02-26 | ROUSH JOHN A | Director | Stock Award | 1 | - |
| 2026-02-26 | LEMAITRE GEORGE W | Chief Executive Officer | Stock Award | 5,609 | - |
| 2026-02-26 | LEMAITRE GEORGE W | Chief Executive Officer | Stock Award | 13 | - |
| 2026-02-26 | PELLEGRINO JOSEPH P JR | Director | Stock Award | 1,893 | - |
| 2026-02-26 | PELLEGRINO JOSEPH P JR | Director | Stock Award | 4 | - |
| 2026-02-26 | JASINSKI LAWRENCE J | Director | Stock Award | 476 | - |
KAMKE TRENT G
Officer
2026-03-11
2,625 shares
·
$284,812
KAMKE TRENT G
Officer
2026-03-11
2,625 shares
·
$93,135
ROBERTS DAVID BRIAN
President
2026-03-11
3,311 shares
·
$356,586
LEBLANC DORIAN PAUL CPA
Chief Financial Officer
2026-03-10
2 shares
LEMAITRE GEORGE W
Chief Executive Officer
2026-03-02
5,000 shares
LEMAITRE GEORGE W
Chief Executive Officer
2026-03-02
205,930 shares
·
$22,043,375
KAMKE TRENT G
Officer
2026-02-27
1,044 shares
·
$115,143
ROBERTS DAVID BRIAN
President
2026-02-27
8,464 shares
·
$903,958
ROUSH JOHN A
Director
2026-02-26
476 shares
ROUSH JOHN A
Director
2026-02-26
1 shares
LEMAITRE GEORGE W
Chief Executive Officer
2026-02-26
5,609 shares
LEMAITRE GEORGE W
Chief Executive Officer
2026-02-26
13 shares
PELLEGRINO JOSEPH P JR
Director
2026-02-26
1,893 shares
PELLEGRINO JOSEPH P JR
Director
2026-02-26
4 shares
JASINSKI LAWRENCE J
Director
2026-02-26
476 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
9 analysts
Barrington Research
2026-02-26
Outperform
Outperform
Roth Capital
2026-02-26
Buy
Buy
Wells Fargo
2026-02-26
Equal-Weight
Equal-Weight
Citizens
2026-02-26
Market Outperform
Market Outperform
Barrington Research
2026-02-20
Outperform
Outperform
Wells Fargo
2025-11-07
Equal-Weight
Equal-Weight
Barrington Research
2025-10-15
Outperform
Outperform
Past News Coverage
Recent headlines mentioning LMAT from our newsroom.
Newest → oldest
No matching news yet.